EUVIMEDEUVIMED entdecken
Crossref

Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Yujiro Nagata, Kazumasa Jojima, Takuo Matsukawa, Ikko Tomisaki, Naohiro Fujimoto

Anticancer Research · 2023

DOI: 10.21873/anticanres.16651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Yujiro Nagata und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan yujiro-nagata@med.uoeh-u.ac.jp. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Phenylthiohydantoin, Prostate-Specific Antigen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantPhenylthiohydantoinProstate-Specific AntigenHumansMaleNitrilesBenzamidesAgedMiddle AgedPrognosisAged, 80 and overNeoplasm MetastasisTreatment OutcomeBiomarkers, Tumor

Stichwörter der Autor:innen

Castration-resistant prostate cancerandrogen-deprivation therapyenzalutamideinitial-to-nadir prostate-specific antigen ratio

Substanzen

NitrilesenzalutamideBenzamidesPhenylthiohydantoinProstate-Specific AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan yujiro-nagata@med.uoeh-u.ac.jp.
  • Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.

Zitieren

APA

Nagata, Y., Jojima, K., Matsukawa, T., Tomisaki, I., & Fujimoto, N. (2023). Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.16651

Vancouver

Nagata Y, Jojima K, Matsukawa T, Tomisaki I, Fujimoto N. Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer. Anticancer Research. 2023. doi:10.21873/anticanres.16651

BibTeX
@article{Nagata2023,
  author = {Nagata, Yujiro and Jojima, Kazumasa and Matsukawa, Takuo and Tomisaki, Ikko and Fujimoto, Naohiro},
  title = {Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16651}
}
Kostenlos starten →